<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524771</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2007_03</org_study_id>
    <nct_id>NCT00524771</nct_id>
  </id_info>
  <brief_title>Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)</brief_title>
  <acronym>TASC</acronym>
  <official_title>Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize and compare the risks of short- and long-term
      use of NuvaRing® with marketed combined oral contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a large, multinational, controlled, prospective, active surveillance study of women
      who are prescribed NuvaRing® or an oral contraceptive (OC). The study follows two cohorts.
      The cohorts consist of new users (starters and switchers) of two different groups of hormonal
      contraceptives:

        -  NuvaRing®

        -  marketed combined OCs (combined oral contraceptives)

      NuvaRing® is a transparent and flexible contraceptive vaginal ring containing etonogestrel
      and ethinylestradiol (EE). The ring releases 15 mcg EE and 120 mcg etonogestrel daily. After
      insertion it remains in the upper part of the vagina for 21 days, followed by 7 ring-free
      days before a new ring is inserted.

      The primary objective of this study is to characterize and compare the risks of short- and
      long-term use of NuvaRing® with marketed combined OCs. The main clinical outcomes of interest
      for the short and long-term follow-up are:

        -  Deep Venous Thrombosis (DVT)

        -  Pulmonary Embolism (PE)

        -  Acute Myocardial Infarction (AMI)

        -  Cerebrovascular Accidents (CVA)

      Secondary objectives are:

        -  to analyze the drug utilization pattern of NuvaRing® and marketed OCs in a study
           population that is representative for typical use of the individual contraceptive
           methods under routine medical conditions

        -  to characterize the baseline risk of users of the individual formulations

        -  to assess the compliance of NuvaRing® users and users of marketed OCs

        -  to analyze the reasons for discontinuing the treatment with NuvaRing® and/or marketed
           OCs.

      The study will use a non-interference approach to provide standardized, comprehensive,
      reliable information on these treatments in a routine clinical practice setting.

      Study participants will be recruited via an international network of more than 1000
      gynecologists. After study entry cohort members will be followed for a period of 30 to 48
      months for rare serious safety outcomes. Regular, active contacts with the cohort members by
      the study team of the Berlin Center for Epidemiology and Health Research (ZEG), Germany will
      provide the necessary information on health-related events or changes in health status (=
      active surveillance).

      Approximately 15,000 subjects per cohort will be recruited by participating physicians in
      order to provide approx. 86,000 women-years (WY) of observation. Subjects will be considered
      for enrollment in this study after the participating physician has determined that NuvaRing®
      or OC use is appropriate. There will be no specific inclusion/exclusion criteria. All women
      who are eligible are to be asked by their physician if they are willing to participate. As
      this a non-interventional study, the possibility to participate in the study should not be
      discussed with the patient before both - physician and patient - agree upon the prescription.

      The study will be conducted in several European countries and the United States.

      The study will be divided into 2 phases: a baseline survey which includes an initial
      consultation at baseline with a participating physician, and a follow-up phase which includes
      two follow-up contacts within the first year and then annual follow-up contacts for up to 4
      years post-baseline.

      The study will maintain scientific independence and will be governed by an independent Safety
      Monitoring and Advisory Council (SMAC). The Berlin Center for Epidemiology and Health
      Research (ZEG) and its research team will be accountable to the council in all scientific
      matters. The members of the council will be international experts in relevant scientific
      fields (e. g., epidemiology, drug safety, gynecology, cardiology, statistics, endocrinology).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Venous Thromboembolism (VTE)</measure>
    <time_frame>Time to event analysis within 48 months</time_frame>
    <description>Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Arterial Thromboembolism (ATE)</measure>
    <time_frame>Time to event analysis within 48 months</time_frame>
    <description>Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">34100</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Users of NuvaRing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Users of combined oral contraceptives</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women prescribed hormonal contraceptives by gynecologists
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women who are prescribed NuvaRing® or a combined oral contraceptive and who are new
             users (Starters, restarters or switchers) of the formulation

        Exclusion Criteria:

          -  women who do not consent to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berlin Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013 Oct;122(4):800-8. doi: 10.1097/AOG.0b013e3182a5ec6b.</citation>
    <PMID>24084537</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>March 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Juergen Dinger, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Contraceptive Vaginal Ring</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NuvaRing</title>
          <description>Users of an etonogestrel-containing and ethinylestradiol-containing vaginal ring</description>
        </group>
        <group group_id="P2">
          <title>Combined Oral Contraceptives (COC)</title>
          <description>Users of combined oral contraceptive pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17084"/>
                <participants group_id="P2" count="17016"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16864">Numbers completed refer to first follow-up. Individual follow-up ranged between 0.5 and 4.0 years.</participants>
                <participants group_id="P2" count="16431">Numbers completed refer to first follow-up. Individual follow-up ranged between 0.5 and 4.0 years.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="585"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="585"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All study participants that were not excluded due to protocol violations.</population>
      <group_list>
        <group group_id="B1">
          <title>NuvaRing</title>
          <description>Users of an etonogestrel-containing and ethinylestradiol-containing vaginal ring</description>
        </group>
        <group group_id="B2">
          <title>Combined Oral Contraceptives (COC)</title>
          <description>Users of combined oral contraceptive pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16864"/>
            <count group_id="B2" value="16431"/>
            <count group_id="B3" value="33295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="7.3"/>
                    <measurement group_id="B2" value="26.9" spread="7.6"/>
                    <measurement group_id="B3" value="27.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16737"/>
                    <measurement group_id="B2" value="16025"/>
                    <measurement group_id="B3" value="32762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16864"/>
                    <measurement group_id="B2" value="16431"/>
                    <measurement group_id="B3" value="33295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8215"/>
                    <measurement group_id="B2" value="7699"/>
                    <measurement group_id="B3" value="15914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8649"/>
                    <measurement group_id="B2" value="8732"/>
                    <measurement group_id="B3" value="17381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Venous Thromboembolism (VTE)</title>
        <description>Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
        <time_frame>Time to event analysis within 48 months</time_frame>
        <population>Study participants that were not excluded due to protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Users of an etonogestrel-containing and ethinylestradiol-containing vaginal ring</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptives (COC)</title>
            <description>Users of combined oral contraceptive pills</description>
          </group>
          <group group_id="O3">
            <title>COC2</title>
            <description>A priori defined subgroup of users of combined oral contraceptive pills without desogestrel or gestodene</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Venous Thromboembolism (VTE)</title>
          <description>Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
          <population>Study participants that were not excluded due to protocol violations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16864"/>
                <count group_id="O2" value="16431"/>
                <count group_id="O3" value="13811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypothesis: VTE hazard ratio for NuvaRing vs. COCs is higher or equal to 2. This analysis represents the a priori defined primary statistical analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a non-inferiority test of two exponential survival curves . These calculations are based on the following assumptions: 1) one-sided α of 0.025; 2) power (1-β) of 0.80; VTE incidence rate of 9.1 VTE/10.000 WY and 4) non-inferiority limit on hazard ratio of 2.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted age, BMI, duration of current use and family history of VTE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tested null hypothesis: VTE hazard ratio for NuvaRing vs. COC2 is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted age, BMI, duration of current use and family history of VTE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Like analysis 1 (see above) but restricted to exposure period of less than 6 months.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted age, BMI, duration of current use and family history of VTE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Like analysis 1 (see above) but restricted to exposure period of 6 - 12 months.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted age, BMI, duration of current use and family history of VTE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Like analysis 1 (see above) but restricted to exposure period of &gt; 12 months.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted age, BMI, duration of current use and family history of VTE.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Arterial Thromboembolism (ATE)</title>
        <description>Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
        <time_frame>Time to event analysis within 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Users of an etonogestrel-containing and ethinylestradiol-containing vaginal ring</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptives (COC)</title>
            <description>Users of combined oral contraceptive pills</description>
          </group>
          <group group_id="O3">
            <title>COC2</title>
            <description>A priori defined subgroup of users of combined oral contraceptive pills without desogestrel or gestodene</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Arterial Thromboembolism (ATE)</title>
          <description>Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16864"/>
                <count group_id="O2" value="16431"/>
                <count group_id="O3" value="13811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>The hazard ratio was adjusted for age, BMI, Smoking, and treated hypertension.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on the primary statistical analysis (see above).</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, smoking, and treated hypertension.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected over a period of 4 years.</time_frame>
      <desc>All study participants were asked for adverse events at each follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>NuvaRing</title>
          <description>Users of an etonogestrel-containing and ethinylestradiol-containing vaginal ring</description>
        </group>
        <group group_id="E2">
          <title>Combined Oral Contraceptives (COC)</title>
          <description>Users of combined oral contraceptive pills</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="577" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="751" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the blood and blood-forming organs</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular system</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine diseases</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive system</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisening, accidents, etc</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscosceletal system &amp; connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms, malignant</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="17016"/>
              </event>
              <event>
                <sub_title>Neoplasms, benign</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric &amp; neurological disorders</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary system</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="17084"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="17016"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16864"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16431"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Juergen Dinger</name_or_title>
      <organization>Center for Epidemiology and Health Research, Germany</organization>
      <phone>0049 (0)30 945 101 20</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

